Literature DB >> 12396894

Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part II.

Marietta Anthony1, Mary J Berg.   

Abstract

There are specific pharmacology issues related to women's unique physiology, including the hormonal changes that occur throughout their life span. Studies have shown alterations in drug metabolism in relation to phase of menstrual cycle, during pregnancy, or after menopause. In the brain, hormones can alter the response to drugs through various mechanisms. Estrogen and other compounds can bind to the estrogen receptor and modulate a wide range of activities within the cell. In addition, animal studies have demonstrated sexual dimorphism in the brain in terms of both the type of response to estrogen and the response as related to timing of administration. Many normal physiological changes that occur during pregnancy can affect pharmacokinetics and pharmacodynamics. These changes during pregnancy are dramatic rises in levels of estrogen and progesterone, increases in maternal blood volume, altered protein binding resulting from a drop in albumin levels, and a rise in levels of other plasma proteins. The field of chronobiology offers a way to study these changes in biological functions. Chronopharmacology is the study of how biological rhythms, particularly 24-hour, menstrual cycle, and annual rhythms, impact the pharmacokinetics and pharmacodynamics of drugs as a function of their timing. Chronopharmacokinetics is the study of the absorption, distribution, metabolism, and elimination of medicines according to the time of day, menstrual cycle, or year. In addition to applying chronobiology to the study of drugs used in women, new technologies were addressed from computer modeling, pharmacogenetics (genetics of the response to drugs), and in vivo drug metabolism studies.

Entities:  

Mesh:

Year:  2002        PMID: 12396894     DOI: 10.1089/152460902760360568

Source DB:  PubMed          Journal:  J Womens Health Gend Based Med        ISSN: 1524-6094


  14 in total

1.  Gender bias in research: how does it affect evidence based medicine?

Authors:  Anita Holdcroft
Journal:  J R Soc Med       Date:  2007-01       Impact factor: 5.344

2.  Comparative Toxicity by Sex Among Children Treated for Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.

Authors:  Kathleen A Meeske; Lingyun Ji; David R Freyer; Paul Gaynon; Kathleen Ruccione; Anna Butturini; Vassilios I Avramis; Stuart Siegel; Yousif Matloub; Nita L Seibel; Richard Sposto
Journal:  Pediatr Blood Cancer       Date:  2015-07-14       Impact factor: 3.167

Review 3.  Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?

Authors:  Wolfgang Aichhorn; Alexandra B Whitworth; Elisabeth M Weiss; Josef Marksteiner
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  The role of the δ GABA(A) receptor in ovarian cycle-linked changes in hippocampus-dependent learning and memory.

Authors:  Jesse D Cushman; Mellissa D Moore; Richard W Olsen; Michael S Fanselow
Journal:  Neurochem Res       Date:  2014-03-26       Impact factor: 3.996

5.  Intrahippocampal muscimol shifts learning strategy in gonadally intact young adult female rats.

Authors:  Molly W McElroy; Donna L Korol
Journal:  Learn Mem       Date:  2005 Mar-Apr       Impact factor: 2.460

6.  The Illinois Women's Health Registry: advancing women's health research and education in Illinois, USA.

Authors:  Sarah Bristol-Gould; Michelle Desjardins; Teresa K Woodruff
Journal:  Womens Health (Lond)       Date:  2010-03

7.  Pharmacogenomics of multigenic diseases: sex-specific differences in disease and treatment outcome.

Authors:  Julia Pinsonneault; Wolfgang Sadée
Journal:  AAPS PharmSci       Date:  2003-11-05

Review 8.  Predicting the clinical relevance of drug interactions from pre-approval studies.

Authors:  Silvio Caccia; Silvio Garattini; Luca Pasina; Alessandro Nobili
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

9.  WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects.

Authors:  Michael W Church; Brian W Blakley; Don L Burgio; Anil K Gupta
Journal:  J Assoc Res Otolaryngol       Date:  2004-05-20

10.  Sex, gender, and health biotechnology: points to consider.

Authors:  Jerome Amir Singh; Sunita Bandewar; Peter A Singer
Journal:  BMC Int Health Hum Rights       Date:  2009-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.